| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2006-10-17 09:06:20 UTC |
|---|
| Update Date | 2022-03-07 02:49:25 UTC |
|---|
| HMDB ID | HMDB0005022 |
|---|
| Secondary Accession Numbers | - HMDB0014321
- HMDB05022
- HMDB14321
|
|---|
| Metabolite Identification |
|---|
| Common Name | Pravastatin |
|---|
| Description | Pravastatin is a member of the drug class of statins, used for lowering cholesterol and preventing cardiovascular disease. Pravastatin was identified originally in a mold called Nocardia autotrophica by researchers of the Sankyo Pharma Inc; An antilipemic fungal metabolite isolated from cultures of Nocardia autotrophica. It acts as a competitive inhibitor of HMG CoA reductase (hydroxymethylglutaryl CoA reductases); In medicine and pharmacology, pravastatin (Pravachol or Selektine) is a member of the drug class of statins, used for lowering cholesterol and preventing cardiovascular disease. |
|---|
| Structure | [H][C@]12[C@H](C[C@H](O)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC(O)=O)OC(=O)[C@@H](C)CC InChI=1S/C23H36O7/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28)/t13-,14-,16+,17+,18+,19-,20-,22-/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| (+)-(3R,5R)-3,5-Dihydroxy-7-[(1S,2S,6S,8S,8ar)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoic acid | ChEBI | | Pravastatin acid | ChEBI | | Pravastatina | ChEBI | | Pravastatine | ChEBI | | Pravastatinum | ChEBI | | Pravator | Kegg | | (+)-(3R,5R)-3,5-Dihydroxy-7-[(1S,2S,6S,8S,8ar)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoate | Generator | | (3R,5R)-7-[(1S,2S,6S,8S,8AR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid | HMDB | | 3beta-Hydroxycompactin | HMDB | | Eptastatin | HMDB | | Mevalothin | HMDB | | Pravachol | HMDB | | Pravastatin sodium | HMDB | | Selektine | HMDB | | Elisor | HMDB | | Nu-pravastatin | HMDB | | Pravasin | HMDB | | Apo pravastatin | HMDB | | Aventis brand OF pravastatin sodium | HMDB | | Bristol-myers squibb brand OF pravastatin sodium | HMDB | | Juste brand OF pravastatin sodium | HMDB | | Lin pravastatin | HMDB | | Mevalotin | HMDB | | Pravastatin monosodium salt, (6 beta)-isomer | HMDB | | Pravastatin sodium salt | HMDB | | Pravastatin, (6 beta)-isomer | HMDB | | RMS-431 | HMDB | | Squibb brand OF pravastatin sodium | HMDB | | Vasten | HMDB | | Apo-pravastatin | HMDB | | Apotex brand OF pravastatin sodium | HMDB | | Linson pharma brand OF pravastatin sodium | HMDB | | Liplat | HMDB | | Lipostat | HMDB | | Nu-pharma brand OF pravastatin sodium | HMDB | | Prareduct | HMDB | | Pravastatin tert-octylamine salt | HMDB | | RMS 431 | HMDB | | Sankyo brand OF pravastatin sodium | HMDB | | Sodium salt, pravastatin | HMDB | | Bristacol | HMDB | | Esteve brand OF pravastatin sodium | HMDB | | Lin-pravastatin | HMDB | | Lipemol | HMDB | | Nu pravastatin | HMDB | | Pravacol | HMDB | | Pravastatin tert octylamine salt | HMDB |
|
|---|
| Chemical Formula | C23H36O7 |
|---|
| Average Molecular Weight | 424.5277 |
|---|
| Monoisotopic Molecular Weight | 424.246103506 |
|---|
| IUPAC Name | (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid |
|---|
| Traditional Name | pravastatin |
|---|
| CAS Registry Number | 81093-37-0 |
|---|
| SMILES | [H][C@]12[C@H](C[C@H](O)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC(O)=O)OC(=O)[C@@H](C)CC |
|---|
| InChI Identifier | InChI=1S/C23H36O7/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28)/t13-,14-,16+,17+,18+,19-,20-,22-/m0/s1 |
|---|
| InChI Key | TUZYXOIXSAXUGO-PZAWKZKUSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as medium-chain hydroxy acids and derivatives. These are hydroxy acids with a 6 to 12 carbon atoms long side chain. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organic acids and derivatives |
|---|
| Class | Hydroxy acids and derivatives |
|---|
| Sub Class | Medium-chain hydroxy acids and derivatives |
|---|
| Direct Parent | Medium-chain hydroxy acids and derivatives |
|---|
| Alternative Parents | |
|---|
| Substituents | - Medium-chain hydroxy acid
- Fatty alcohol
- Medium-chain fatty acid
- Hydroxy fatty acid
- Fatty acid ester
- Branched fatty acid
- Beta-hydroxy acid
- Fatty acyl
- Dicarboxylic acid or derivatives
- Secondary alcohol
- Carboxylic acid ester
- Carboxylic acid
- Carboxylic acid derivative
- Organic oxygen compound
- Organic oxide
- Hydrocarbon derivative
- Organooxygen compound
- Carbonyl group
- Alcohol
- Aliphatic homopolycyclic compound
|
|---|
| Molecular Framework | Aliphatic homopolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Not Available | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 326 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.24 g/L | Not Available | | LogP | 2.2 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 5.66 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 12.8906 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.9 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2553.8 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 178.1 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 159.4 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 156.9 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 125.2 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 540.8 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 487.8 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 106.6 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1020.0 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 500.2 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1552.3 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 312.5 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 367.0 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 299.4 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 200.3 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 56.0 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Pravastatin,1TMS,isomer #1 | CC[C@H](C)C(=O)O[C@H]1C[C@H](O[Si](C)(C)C)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21 | 3177.6 | Semi standard non polar | 33892256 | | Pravastatin,1TMS,isomer #2 | CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@H](C[C@@H](O)CC(=O)O)O[Si](C)(C)C)[C@H]21 | 3188.4 | Semi standard non polar | 33892256 | | Pravastatin,1TMS,isomer #3 | CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@H](CC(=O)O)O[Si](C)(C)C)[C@H]21 | 3159.8 | Semi standard non polar | 33892256 | | Pravastatin,1TMS,isomer #4 | CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O[Si](C)(C)C)[C@H]21 | 3202.4 | Semi standard non polar | 33892256 | | Pravastatin,2TMS,isomer #1 | CC[C@H](C)C(=O)O[C@H]1C[C@H](O[Si](C)(C)C)C=C2C=C[C@H](C)[C@H](CC[C@H](C[C@@H](O)CC(=O)O)O[Si](C)(C)C)[C@H]21 | 3210.0 | Semi standard non polar | 33892256 | | Pravastatin,2TMS,isomer #2 | CC[C@H](C)C(=O)O[C@H]1C[C@H](O[Si](C)(C)C)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@H](CC(=O)O)O[Si](C)(C)C)[C@H]21 | 3188.9 | Semi standard non polar | 33892256 | | Pravastatin,2TMS,isomer #3 | CC[C@H](C)C(=O)O[C@H]1C[C@H](O[Si](C)(C)C)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O[Si](C)(C)C)[C@H]21 | 3212.3 | Semi standard non polar | 33892256 | | Pravastatin,2TMS,isomer #4 | CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@H](C[C@H](CC(=O)O)O[Si](C)(C)C)O[Si](C)(C)C)[C@H]21 | 3179.7 | Semi standard non polar | 33892256 | | Pravastatin,2TMS,isomer #5 | CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@H](C[C@@H](O)CC(=O)O[Si](C)(C)C)O[Si](C)(C)C)[C@H]21 | 3207.2 | Semi standard non polar | 33892256 | | Pravastatin,2TMS,isomer #6 | CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@H](CC(=O)O[Si](C)(C)C)O[Si](C)(C)C)[C@H]21 | 3187.4 | Semi standard non polar | 33892256 | | Pravastatin,3TMS,isomer #1 | CC[C@H](C)C(=O)O[C@H]1C[C@H](O[Si](C)(C)C)C=C2C=C[C@H](C)[C@H](CC[C@H](C[C@H](CC(=O)O)O[Si](C)(C)C)O[Si](C)(C)C)[C@H]21 | 3214.3 | Semi standard non polar | 33892256 | | Pravastatin,3TMS,isomer #2 | CC[C@H](C)C(=O)O[C@H]1C[C@H](O[Si](C)(C)C)C=C2C=C[C@H](C)[C@H](CC[C@H](C[C@@H](O)CC(=O)O[Si](C)(C)C)O[Si](C)(C)C)[C@H]21 | 3229.4 | Semi standard non polar | 33892256 | | Pravastatin,3TMS,isomer #3 | CC[C@H](C)C(=O)O[C@H]1C[C@H](O[Si](C)(C)C)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@H](CC(=O)O[Si](C)(C)C)O[Si](C)(C)C)[C@H]21 | 3216.7 | Semi standard non polar | 33892256 | | Pravastatin,3TMS,isomer #4 | CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@H](C[C@H](CC(=O)O[Si](C)(C)C)O[Si](C)(C)C)O[Si](C)(C)C)[C@H]21 | 3196.6 | Semi standard non polar | 33892256 | | Pravastatin,4TMS,isomer #1 | CC[C@H](C)C(=O)O[C@H]1C[C@H](O[Si](C)(C)C)C=C2C=C[C@H](C)[C@H](CC[C@H](C[C@H](CC(=O)O[Si](C)(C)C)O[Si](C)(C)C)O[Si](C)(C)C)[C@H]21 | 3240.9 | Semi standard non polar | 33892256 | | Pravastatin,1TBDMS,isomer #1 | CC[C@H](C)C(=O)O[C@H]1C[C@H](O[Si](C)(C)C(C)(C)C)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21 | 3414.9 | Semi standard non polar | 33892256 | | Pravastatin,1TBDMS,isomer #2 | CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@H](C[C@@H](O)CC(=O)O)O[Si](C)(C)C(C)(C)C)[C@H]21 | 3447.2 | Semi standard non polar | 33892256 | | Pravastatin,1TBDMS,isomer #3 | CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@H](CC(=O)O)O[Si](C)(C)C(C)(C)C)[C@H]21 | 3408.8 | Semi standard non polar | 33892256 | | Pravastatin,1TBDMS,isomer #4 | CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O[Si](C)(C)C(C)(C)C)[C@H]21 | 3467.1 | Semi standard non polar | 33892256 | | Pravastatin,2TBDMS,isomer #1 | CC[C@H](C)C(=O)O[C@H]1C[C@H](O[Si](C)(C)C(C)(C)C)C=C2C=C[C@H](C)[C@H](CC[C@H](C[C@@H](O)CC(=O)O)O[Si](C)(C)C(C)(C)C)[C@H]21 | 3662.8 | Semi standard non polar | 33892256 | | Pravastatin,2TBDMS,isomer #2 | CC[C@H](C)C(=O)O[C@H]1C[C@H](O[Si](C)(C)C(C)(C)C)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@H](CC(=O)O)O[Si](C)(C)C(C)(C)C)[C@H]21 | 3640.0 | Semi standard non polar | 33892256 | | Pravastatin,2TBDMS,isomer #3 | CC[C@H](C)C(=O)O[C@H]1C[C@H](O[Si](C)(C)C(C)(C)C)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O[Si](C)(C)C(C)(C)C)[C@H]21 | 3672.6 | Semi standard non polar | 33892256 | | Pravastatin,2TBDMS,isomer #4 | CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@H](C[C@H](CC(=O)O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C)[C@H]21 | 3652.5 | Semi standard non polar | 33892256 | | Pravastatin,2TBDMS,isomer #5 | CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@H](C[C@@H](O)CC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C)[C@H]21 | 3692.8 | Semi standard non polar | 33892256 | | Pravastatin,2TBDMS,isomer #6 | CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@H](CC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C)[C@H]21 | 3672.3 | Semi standard non polar | 33892256 | | Pravastatin,3TBDMS,isomer #1 | CC[C@H](C)C(=O)O[C@H]1C[C@H](O[Si](C)(C)C(C)(C)C)C=C2C=C[C@H](C)[C@H](CC[C@H](C[C@H](CC(=O)O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C)[C@H]21 | 3871.4 | Semi standard non polar | 33892256 | | Pravastatin,3TBDMS,isomer #2 | CC[C@H](C)C(=O)O[C@H]1C[C@H](O[Si](C)(C)C(C)(C)C)C=C2C=C[C@H](C)[C@H](CC[C@H](C[C@@H](O)CC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C)[C@H]21 | 3890.1 | Semi standard non polar | 33892256 | | Pravastatin,3TBDMS,isomer #3 | CC[C@H](C)C(=O)O[C@H]1C[C@H](O[Si](C)(C)C(C)(C)C)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@H](CC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C)[C@H]21 | 3877.8 | Semi standard non polar | 33892256 | | Pravastatin,3TBDMS,isomer #4 | CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@H](C[C@H](CC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C)[C@H]21 | 3885.0 | Semi standard non polar | 33892256 | | Pravastatin,4TBDMS,isomer #1 | CC[C@H](C)C(=O)O[C@H]1C[C@H](O[Si](C)(C)C(C)(C)C)C=C2C=C[C@H](C)[C@H](CC[C@H](C[C@H](CC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C)[C@H]21 | 4074.5 | Semi standard non polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Pravastatin GC-MS (Non-derivatized) - 70eV, Positive | splash10-0a4i-6194400000-5f7280491acf9312a516 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Pravastatin GC-MS (3 TMS) - 70eV, Positive | splash10-004i-8202269000-c5995d4b5b537e3a6f6e | 2017-10-06 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Pravastatin GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Pravastatin LC-ESI-ITFT , negative-QTOF | splash10-0uk9-0009000000-967b377abafe64b73071 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pravastatin LC-ESI-ITFT , negative-QTOF | splash10-00di-0002900000-bd7fd66d793ae64426ff | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pravastatin LC-ESI-ITFT , negative-QTOF | splash10-0udi-4809000000-0ed5a8797dfc49ecf5af | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pravastatin LC-ESI-ITFT , negative-QTOF | splash10-0udi-2900000000-91b125182ce5d90f16ab | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pravastatin LC-ESI-ITFT , negative-QTOF | splash10-0udi-1900000000-e8fc6384260de93c5aa8 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pravastatin LC-ESI-ITFT , negative-QTOF | splash10-0udi-1900000000-11e99968bc0ba393b6f9 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pravastatin LC-ESI-ITFT , negative-QTOF | splash10-0udi-4900000000-0e4265e6dc1468c1471d | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pravastatin LC-ESI-ITFT , negative-QTOF | splash10-00di-0002900000-8795ee00dded0ef8be48 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pravastatin LC-ESI-ITFT , negative-QTOF | splash10-0udi-3709000000-aa45be15af0471c0a46e | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pravastatin LC-ESI-ITFT , negative-QTOF | splash10-0udi-2900000000-5617409991f5c58e5130 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pravastatin LC-ESI-ITFT , negative-QTOF | splash10-0udi-2900000000-2bf5c13979a639625d1c | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pravastatin LC-ESI-ITFT , negative-QTOF | splash10-0udi-2900000000-9a233e521607e82ab7a0 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pravastatin LC-ESI-ITFT , negative-QTOF | splash10-0udi-0900000000-2083dfbb67bf2b03ccf9 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pravastatin LC-ESI-ITFT , negative-QTOF | splash10-0uk9-0009000000-4b2c09a295ba7f3ce41b | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pravastatin LC-ESI-QFT , negative-QTOF | splash10-00di-0607900000-e57e263ad3f74bfda195 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pravastatin 35V, Negative-QTOF | splash10-0uk9-0209000000-e1f3357e6db2a045c733 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pravastatin 35V, Positive-QTOF | splash10-053r-0890100000-343e9a2af9d9e56f3078 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pravastatin 15V, Negative-QTOF | splash10-0fk9-3209000000-4e7af37985a2d2fdf90c | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Pravastatin 30V, Negative-QTOF | splash10-0pb9-9600000000-1e8b86b20daa312fd4c0 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pravastatin 10V, Positive-QTOF | splash10-052r-1009600000-9928021021dc6868847d | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pravastatin 20V, Positive-QTOF | splash10-052r-4019100000-bea6aa9fed446c2cdd3c | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pravastatin 40V, Positive-QTOF | splash10-052r-9023000000-7b0213c49b76e864814e | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pravastatin 10V, Negative-QTOF | splash10-05fr-1007900000-cb1ad55355bd717f1c23 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pravastatin 20V, Negative-QTOF | splash10-0a4i-5209300000-f017d063b98b59e6d5f1 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pravastatin 40V, Negative-QTOF | splash10-0a4i-9244000000-d95d5ae750ad620ba728 | 2016-08-03 | Wishart Lab | View Spectrum |
|
|---|
| General References | - Pokrovskaia EV, Vaulin NA, Gratsianskii NA, Averkov OV, Deev AD: [Markers of inflammation and platelet aggregation in patients with non ST elevation acute coronary syndrome treated with atorvastatin or pravastatin]. Kardiologiia. 2003;43(1):7-18. [PubMed:12891281 ]
- Tonelli M, Sacks F, Pfeffer M, Jhangri GS, Curhan G: Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int. 2005 Jul;68(1):237-45. [PubMed:15954913 ]
- Peverill RE, Smolich JJ, Malan E, Goldstat R, Davis SR: Comparison of effects of pravastatin and hormone therapy on soluble P-selectin and platelet P-selectin expression in postmenopausal hypercholesterolemic women. Maturitas. 2006 Jan 20;53(2):158-65. [PubMed:16368469 ]
- Gaugler MH, Vereycken-Holler V, Squiban C, Vandamme M, Vozenin-Brotons MC, Benderitter M: Pravastatin limits endothelial activation after irradiation and decreases the resulting inflammatory and thrombotic responses. Radiat Res. 2005 May;163(5):479-87. [PubMed:15850408 ]
- Bruni F, Puccetti L, Pasqui AL, Pastorelli M, Bova G, Cercignani M, Palazzuoli A, Leo A, Auteri A: Different effect induced by treatment with several statins on monocyte tissue factor expression in hypercholesterolemic subjects. Clin Exp Med. 2003 May;3(1):45-53. [PubMed:12748879 ]
- Tonelli M, Isles C, Craven T, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, West M, Packard C, Curhan GC: Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation. 2005 Jul 12;112(2):171-8. Epub 2005 Jul 5. [PubMed:15998677 ]
- (). FDA label . .
|
|---|